- freely available
- re-usable
Nanomaterials 2012, 2(3), 217-250; doi:10.3390/nano2030217
Review
Rafts, Nanoparticles and Neural Disease
1
Ross University School of Medicine, Miami Beach Community Health Center, 11645 Biscayne Boulevard, North Miami, FL 33181, USA
2
Department of Anthropology, University of Central Florida, Orlando, FL 32816, USA
* Author to whom correspondence should be addressed.
Received: 12 June 2012; in revised form: 19 July 2012 / Accepted: 20 July 2012 / Published: 6 August 2012
Abstract: This review examines the role of membrane rafts in neural disease as a rationale for drug targeting utilizing lipid-based nanoparticles. The article begins with an overview of methodological issues involving the existence, sizes, and lifetimes of rafts, and then examines raft function in the etiologies of three major neural diseases—epilepsy, Parkinson’s disease, and Alzheimer’s disease—selected as promising candidates for raft-based therapeutics. Raft-targeting drug delivery systems involving liposomes and solid lipid nanoparticles are then examined in detail.
Keywords: rafts; nanoparticles; nanomedicine; neural disease; epilepsy; Parkinson’s disease, Alzheimer’s disease; liposomes; solid lipid nanoparticles
Article Statistics
Click here to load and display the download statistics.Cite This Article
MDPI and ACS Style
Gulati, V.; Wallace, R. Rafts, Nanoparticles and Neural Disease. Nanomaterials 2012, 2, 217-250.
AMA StyleGulati V, Wallace R. Rafts, Nanoparticles and Neural Disease. Nanomaterials. 2012; 2(3):217-250.
Chicago/Turabian StyleGulati, Vishal; Wallace, Ron. 2012. "Rafts, Nanoparticles and Neural Disease." Nanomaterials 2, no. 3: 217-250.
Nanomaterials
EISSN 2079-4991
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert
